Dergiler / Marmara Medical Journal / 2022 / Cilt: 35 - Sayı: 3

Thyroid diseases in patients with active endogenous Cushing’s syndrome

Sayfa
257–262
Yayın Tarihi
2022-10-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although, hypercortisolism has an impact on hypothalamic-hypophyseal-thyroid axis, its clinical implication does not seem to be significant.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Data about the impact of Cushing’s syndrome (CS) on thyroid is scarce.
📊
Temel Bulgular & Veri:Patients and Methods: Nineteen patients with CS and 40 healthy participants were included in the study.
💡
Sonuç & Katkı:Although, hypercortisolism has an impact on hypothalamic-hypophyseal-thyroid axis, its clinical implication does not seem to be significant.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Cushing’s syndrome · Thyroid diseases · Thyroid nodule

Abstract

Objective: Data about the impact of Cushing’s syndrome (CS) on thyroid is scarce. We aimed to identify the prevalence of thyroid diseases in patients with CS. Patients and Methods: Nineteen patients with CS and 40 healthy participants were included in the study. All patients were tested for free tri-iodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin (anti-Tg), and antithyroid peroxidase (anti-TPO) levels, and thyroid ultrasonography (US). Results: Overt hypothyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism was evident in 5.3%, 5.3%, and 21.1% of patients with CS; and 2.5%, 7.5%, and 15% of healthy subjects, respectively. fT3 and fT4 levels were lower in patients with CS. None of the patients with CS and 27.5% of the control group had autoimmune thyroid disease (AITD), which was demonstrated by both US findings and anti-TPO positivity (P=0.01). Frequency of thyroid nodule was 52.6% and 52.5% in patients with CS and controls, respectively (P=0.99). Conclusion: The prevalence of thyroid dysfunction, nodular thyroid disease, and goiter is comparable to healthy population. However, AITD is less prevalent among patients with CS. Although, hypercortisolism has an impact on hypothalamic-hypophyseal-thyroid axis, its clinical implication does not seem to be significant.

🔖

Bu Makaleye Atıf Yap

TOPTAS, T., KAHRAMAN, K. B., TOPCU, Z., BOSTAN, H., KADIOGLU, P. (2022). Thyroid diseases in patients with active endogenous Cushing’s syndrome. Marmara Medical Journal, Cilt: 35 - Sayı: 3, 257–262. https://ajindex.com/articles/688225

Kaynakça (4)

  1. Dogansen SC, Yalin GY, Canbaz B, Tanrikulu S, Yarman S. Dynamic changes of central thyroid functions in the management of Cushing’s syndrome. Arch Endocrinol Metab 2018;62:164-71. doi: 10.20945/2359.399.7000000019. PMID: 29641732. Nicoloff JT, Fisher DA, Appleman MD Jr. The role of glucocorticoids in the regulation of thyroid function in man. J Clin Invest 1970;49:1922-9. doi: 10.1172/JCI106411. Roelfsema F, Pereira AM, Biermasz NR, et al. Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing’s syndrome. Eur J Endocrinol 2009;161:695- 703. doi: 10.1530/EJE-09-0580.
  2. Shimokaze T, Toyoshima K, Shibasaki J, et al. TSH suppression after intravenous glucocorticosteroid administration in preterm infants. J Pediatr Endocrinol Metab 2012;25:853-7. doi: 10.1515/jpem-2012-0075. Bános C, Takó J, Salamon F, Györgyi S, Czikkely R. Effect of ACTH-stimulated glucocorticoid hypersecretion on the serum concentrations of thyroxine-binding globulin, thyroxine, triiodothyronine, reverse triiodothyronine and on the TSH-response to TRH. Acta Med Acad Sci Hung 1979; 36:381-94.
  3. Shekhar S, McGlotten R, Auh S, Rother KI, Nieman LK. The hypothalamic-pituitary-thyroid axis in Cushing syndrome before and after curative surgery. J Clin Endocrinol Metab 2021; 106:e1316-e1331. doi: 10.1210/clinem/dgaa858. da Mota F, Murray C, Ezzat S. Overt immune dysfunction after Cushing’s syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab; 96(10):E1670-4 2011. doi: 10.1210/jc.2011-1317.
  4. Russo L, Vitti P, Pinchera A, Marinò M. Exacerbation of autoimmune thyroiditis following bilateral adrenalectomy for Cushing’s syndrome. Thyroid 2010; 20:669-70. doi: 10.1089/ thy.2010.0040. Arikan E, Guldiken S, Altun BU, Kara M, Tugrul A. Exacerbations of Graves’ disease after unilateral adrenalectomy for Cushing’s syndrome. J Endocrinol Invest 2004;27:574-6. doi: 10.1007/BF03347482. Takasu N, Komiya I, Nagasawa Y, Asawa T, Yamada T. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing’s syndrome due to an adrenocortical adenoma. N Engl J Med 1990; 322:1708-12. doi: 10.1056/NEJM199.006.143222404. Onal ED, Sacikara M, Saglam F, Ersoy R, Cakir B. Primary thyroid disorders in patients with endogenous hypercortisolism: an observational study. Int J Endocrinol 2014:732736. doi: 10.1155/2014/732736. Invitti C, Manfrini R, Romanini BM, Cavagnini F. High prevalence of nodular thyroid disease i